Send to

Choose Destination
Immunol Rev. 2017 Jan;275(1):324-333. doi: 10.1111/imr.12478.

Antibody gene transfer with adeno-associated viral vectors as a method for HIV prevention.

Author information

Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, USA.
Division of Biology and Biological Engineering, California Institute of Technology, Pasadena, CA, USA.


Broadly neutralizing antibodies (bNAbs) against human immunodeficiency virus (HIV) show great promise in HIV prevention as they are capable of potently neutralizing a considerable breadth of genetically diverse strains. Passive transfer of monoclonal bNAb proteins can confer protection in animal models of HIV infection at modest concentrations, inspiring efforts to develop an HIV vaccine capable of eliciting bNAb responses. However, these antibodies demonstrate high degrees of somatic mutation and other unique characteristics that may hinder the ability of conventional approaches to consistently and effectively produce bNAb analogs. As an alternative strategy, we and others have proposed vector-mediated gene transfer to generate long-term, systemic production of bNAbs in the absence of immunization. Herein, we review the use of adeno-associated virus (AAV) vectors for delivery of HIV bNAbs and antibody-like proteins and summarize both the advantages and disadvantages of this strategy as a method for HIV prevention.


HIV ; adeno-associated virus; antibody gene transfer; broadly neutralizing antibodies; immunoprophylaxis

[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Wiley Icon for PubMed Central
Loading ...
Support Center